ScreenerHero

CRVOCervoMed Inc. Common Stock

NAS · US · Healthcare · Biotechnology · cervomed.com
2.620USD-3.32%Mkt Cap: 39.61M $P/E: —

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered s…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap39.61M $
Enterprise Value13.77M $
Revenue (TTM)331.30K $
Gross Profit-21.50M $
Net Income (TTM)-26.97M $
Revenue/Share0.0350 USD
Last Price2.620 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees15
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.74
PEG—
EV/EBITDA—
EV/Revenue41.55
P/S116.83
P/B1.51
EPS (TTM)-3.01
EPS (Forward)-1.48
52W Range
2.1455% of range11.25
52W High11.25 USD
52W Low2.145 USD
Profitability
Gross Margin0.00%
Oper. Margin-9406.96%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-147.98%
ROA-117.87%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-23.45M $
CapEx (TTM)—
FCF Margin-4916.94%
FCF Yield-41.12%
Net Debt-24.94M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio8.57
Quick Ratio8.22
Book Value/Sh1.697 USD
Cash/Share1.649 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateDec 14, 2018
Splits
Last Split2:3
Split DateAug 17, 2023
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)15.80 USD
Upside (mean)+503.1%
Target Range9.000 USD – 25.00 USD
$9.000+503.1% to mean$25.00
# Analysts5
Ownership
Shares Out.15.12M
Float11.20M
Insiders26.43%
Institutions22.29%
Short Interest
Short Ratio1.5d
Short % Float7.83%
Short % Out.6.15%
Shares Short832.42K
Short (prev mo.)807.56K
Technical
SMA 503.052 (-14.2%)
SMA 2004.900 (-46.5%)
Beta-4.31
S&P 52W Chg18.16%
Avg Vol (30d)464.77K
Avg Vol (10d)420.70K
Technical Indicators
RSI (14)42.2
MACD-0.0834
MACD Signal-0.0886
MACD Hist.+0.0052
BB Upper3.069 USD
BB Middle2.729 USD
BB Lower2.390 USD
BB Width24.91%
ATR (14)0.2652 USD
Vol Ratio (20d)0.73x